BRD2 and arthritic joint disease: Although high-dose triptolide demonstrates significant anti-inflammatory effects (IL-6, IL-17A), it shows limited efficacy in improving arthritis scores and induces severe ovarian dysfunction (E2, estrous cycle), While low-dose triptolide reduces arthritis scores and lowers IL-6 and IL-17A levels, its significant elevation of FSH and disruption of estrous cyclicity render it non-ideal as a therapeutic dosage.